Status:
RECRUITING
Novel Glaucoma Diagnostics
Lead Sponsor:
Wills Eye
Collaborating Sponsors:
National Eye Institute (NEI)
Conditions:
Glaucoma
Macular Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will tes...
Detailed Description
Objective: The purpose of this research is to evaluate a new technology, optical coherence tomography (OCT), to image diseases of the eye and to compare the measurements obtained using OCT with those...
Eligibility Criteria
Inclusion
- Ability to provide informed consent and to understand the study procedures
- Healthy volunteers
- Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
- (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.
Exclusion
- Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
- Strabismus, nystagmus, or any condition that prevents fixation.
- Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
- History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.
Key Trial Info
Start Date :
August 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2029
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT00286637
Start Date
August 1 2000
End Date
July 31 2029
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wills Eye Hospital
Philadelphia, Pennsylvania, United States, 19107